Merck (MRK) Total Non-Current Liabilities (2009 - 2026)
Merck (MRK) reported Total Non-Current Liabilities of $75.1 billion for Q1 2026, up 25.05% year-over-year from $60.1 billion in Q1 2025, and down 1.91% on a QoQ basis from $76.6 billion in Q4 2025.
Merck (MRK) has 17 years of Total Non-Current Liabilities data on file, last reported at $75.1 billion in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 25.05% year-over-year to $75.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.1 billion (up 25.05% YoY) and the FY2025 annual result came in at $76.6 billion, changed N/A from the prior year.
- Total Non-Current Liabilities declined to $75.1 billion in Q1 2026 per MRK's latest filing, from $76.6 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $76.6 billion in Q4 2025 and bottomed at $600.0 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $675.0 million (2022), against an average of $24.9 billion.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities changed 0.0%; it then surged 7908.93% in 2025.
- Tracing MRK's Total Non-Current Liabilities over 5 years: stood at $600.0 million in 2022, then rose by 25.0% to $750.0 million in 2023, then changed by 0.0% to $750.0 million in 2024, then jumped by 10109.6% to $76.6 billion in 2025, then dropped by 1.91% to $75.1 billion in 2026.
- Per Business Quant, the three latest MRK Total Non-Current Liabilities figures stand at $75.1 billion (Q1 2026), $76.6 billion (Q4 2025), and $70.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 100.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 31.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.11 Bn |
| Dec 31, 2025 | 76.57 Bn |
| Sep 30, 2025 | 69.98 Bn |
| Jun 30, 2025 | 61.43 Bn |
| Mar 31, 2025 | 60.07 Bn |
| Mar 31, 2024 | 750.00 Mn |
| Dec 31, 2023 | 750.00 Mn |
| Sep 30, 2023 | 600.00 Mn |
| Jun 30, 2023 | 600.00 Mn |
| Mar 31, 2023 | 600.00 Mn |
| Dec 31, 2022 | 600.00 Mn |
| Sep 30, 2022 | 600.00 Mn |
| Jun 30, 2022 | 600.00 Mn |
| Mar 31, 2022 | 600.00 Mn |
| Mar 31, 2021 | 400.00 Mn |
| Dec 31, 2020 | 600.00 Mn |
| Sep 30, 2020 | 400.00 Mn |
| Jun 30, 2020 | 570.00 Mn |
| Mar 31, 2020 | 375.00 Mn |
| Dec 31, 2019 | 375.00 Mn |
| Sep 30, 2019 | 55.65 Bn |
| Jun 30, 2019 | -453.00 Mn |
| Mar 31, 2019 | -385.00 Mn |
| Dec 31, 2018 | -520.00 Mn |
| Sep 30, 2018 | 51.62 Bn |
| Jun 30, 2018 | 51.44 Bn |
| Mar 31, 2018 | 51.77 Bn |
| Dec 31, 2017 | 52.37 Bn |
| Sep 30, 2017 | 45.46 Bn |
| Jun 30, 2017 | 45.02 Bn |
| Mar 31, 2017 | 93.32 Bn |
| Dec 31, 2016 | 46.56 Bn |
| Sep 30, 2016 | 45.59 Bn |
| Jun 30, 2016 | 95.96 Bn |
| Mar 31, 2016 | 93.82 Bn |
| Dec 31, 2015 | 49.57 Bn |
| Sep 30, 2015 | 47.67 Bn |
| Jun 30, 2015 | 48.03 Bn |
| Mar 31, 2015 | 52.75 Bn |
| Dec 31, 2014 | 41.56 Bn |
| Sep 30, 2014 | 49.48 Bn |
| Jun 30, 2014 | 41.17 Bn |
| Mar 31, 2014 | 47.94 Bn |
| Dec 31, 2013 | 45.18 Bn |
| Mar 31, 2013 | -55.75 Bn |
| Dec 31, 2012 | 40.34 Bn |
| Sep 30, 2012 | -58.39 Bn |
| Dec 31, 2011 | 48.08 Bn |
| Sep 30, 2009 | 12.56 Bn |
| Jun 30, 2009 | 12.32 Bn |